Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Specifically targeted engineered exosomes loaded with circAKR1A1 enhance tumorigenesis and metastasis in prostate cancer by activating the PI3K/Akt signalling pathway.

Oncogene·2026
Same author

Exploring immune-inflammatory cross-talk in atherosclerosis using AI-enhanced multi-omics approaches.

Clinical and experimental medicine·2026
Same author

Semiology Timing and Seizure Patterns: Improving Surgical Decision Making in Insular Epilepsy.

Annals of neurology·2025
Same author

Refining the interpretation of drug survival and safety in VEXAS syndrome: the importance of competing risks and exposure time. Comment on the article by Eviatar et al.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Neocortical LBD in Women and Episodic Memory Decline in Men: Clarifying Sex Effects.

Annals of neurology·2025
Same author

Letter on 'Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis'.

Alimentary pharmacology & therapeutics·2025

Related Experiment Video

Updated: Jul 16, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Integrated Engineering of CAR-T Cells for Solid Tumours.

Chao Yang1, Tan Li2, Ping He3

  • 1Trauma Center and Department of Burns, The First Hospital of China Medical University, Shenyang, Liaoning, China.

Cell Proliferation
|July 15, 2026
PubMed
Summary

Next-generation CAR T-cell therapies are engineered for solid tumors by integrating controllable activation, enhanced resilience, and tumor microenvironment modulation. This adaptive approach aims to overcome challenges and improve efficacy against solid cancers.

Keywords:
CAR‐T cellmetabolic reprogrammingregional deliverysolid tumourstumour microenvironment (TME)

More Related Videos

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Related Experiment Videos

Last Updated: Jul 16, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • CAR T-cell therapy shows success in blood cancers but faces challenges in solid tumors.
  • Obstacles include antigen heterogeneity, a suppressive tumor microenvironment (TME), and T-cell dysfunction.

Purpose of the Study:

  • To review the evolution of CAR T-cell engineering from single-axis to integrated frameworks for solid tumors.
  • To explore strategies for overcoming TME-mediated resistance and T-cell exhaustion.

Main Methods:

  • Delineation of next-generation CAR T-cell designs with logic-gated and pharmacologically regulatable receptors.
  • Assessment of metabolic and epigenetic reprogramming for enhanced T-cell resilience.
  • Evaluation of TME modulation strategies, including cell depletion and biomaterial scaffolds.

Main Results:

  • Integrated CAR T-cell systems combine controllable activation, intrinsic resilience, and TME modulation.
  • These adaptive systems aim to dynamically respond to evolving tumor ecosystems.
  • Strategies are being developed to narrow the efficacy gap between hematologic and solid cancers.

Conclusions:

  • Successful clinical implementation requires managing toxicities like cytokine release syndrome (CRS).
  • Advanced monitoring technologies are crucial for supporting these therapies.
  • Rational combinations of strategies are key to advancing cellular therapies for solid tumors.